Clinical Trial Update: Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for PCAR-019 evaluating efficacy and safety in CD19-positive relapsed or refractory leukemia and lymphoma across Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Prolymphocytic Leukemia
• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• PCAR-019

Snippet

Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Conditions: Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 1, Phase 2 | Status: UNKNOWN